A Randomized, Investigator and Subject Blinded, Sponsor Unblinded Placebo-Controlled Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2018
At a glance
- Drugs TAK 831 (Primary)
- Indications Ataxia; Friedreich's ataxia; Schizophrenia
- Focus Adverse reactions
- Sponsors Takeda
- 20 Sep 2018 Status changed from recruiting to completed.
- 26 Aug 2018 Planned End Date changed from 30 Jul 2018 to 14 Sep 2018.
- 26 Aug 2018 Planned primary completion date changed from 30 Jul 2018 to 14 Sep 2018.